Madrigal Pharmaceuticals (MDGL) announced that the European Commission has granted conditional marketing authorization for Rezdiffra for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities
- Novo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease
- Madrigal Pharmaceuticals: Strong Buy Rating Backed by Rezdiffra’s Market Success and Strategic Expansion
- Madrigal Pharmaceuticals price target raised to $523 from $458 at UBS
- Madrigal Pharmaceuticals Reports Strong Growth Amid Challenges